Given the prognostic implication of the gain-of-function KIT mutations, and over-expression of KIT observed in most CBF-AML including those with KIT mutations (48), studies have explored the addition of KIT inhibitors such as dasatinib and avapritinib to frontline therapy (49) to improve the outcome. This evidence concerns the gene CEBPZ and acute myeloid leukemia.